CDK4/6抑制剂治疗HR+/HER2-晚期乳腺癌的效果及安全性研究  

Efficacy and safety of CDK4/6 inhibitors in HR+/HER2-advanced breast cancer patients

作　　者：倪静怡[1] 陈佳[1] 张葆春 高湘湘[1] 金聪慧[1] NI Jingyi;CHEN Jia;ZHANG Baochun;GAO Xiangxiang;JIN Conghui(Department of Oncology,Affiliated Tumor Hospital of Nantong University,Nantong Tumor Hospital,Jiangsu Province,Nantong 226361)

机构地区：[1]南通大学附属肿瘤医院,江苏省南通市肿瘤医院乳腺内科,南通226361

出　　处：《南通大学学报（医学版）》2023年第2期148-151,共4页Journal of Nantong University(Medical sciences)

基　　金：南通市卫生健康委指导性项目(MSZ2022024)。

摘　　要：目的:探讨阿贝西利联合内分泌药物治疗在激素受体阳性/人类表皮生长因子受体2阴性(hormone receptor positive/human epidermal growth factor receptor-2 negative,HR+/HER2-)晚期乳腺癌患者中的临床疗效及不良反应。方法:回顾性分析2021年2月—2022年9月在南通大学附属肿瘤医院接受阿贝西利联合内分泌治疗的70例HR+/HER2-晚期乳腺癌患者的临床病理资料。单因素及多因素Cox比例风险模型分析影响患者无进展生存期(progression-free survival,PFS)的独立预后因素,总结治疗中的不良反应。结果:70例HR+/HER2-晚期乳腺癌中接受阿贝西利治疗>6个月的患者30例(42.9%),客观缓解率为44.3%,疾病控制率为67.1%。与阿贝西利一线治疗组相比,哌柏西利转阿贝西利组PFS的HR为5.4(95%CI:1.1~26.4,P=0.04)。不良反应以白细胞减少(42.9%)和腹痛腹泻(10.0%)最常见。结论:阿贝西利联合内分泌药物治疗HR+/HER2-晚期乳腺癌患者具有良好的疗效,且不良反应可控,耐受性良好。Objective:To evaluate the efficacy and adverse effects of the treatment of Abemaciclib and endocrine therapy in hormone receptor positive/human epidermal growth factor receptor 2 negative(HR+/HER2-)advanced breast cancer patients.Methods:Clinical data pathological of HR+/HER2-breast cancer patients received Abemaciclib and endocrine therapy in Affiliated Tumor Hospital of Nantong University between February 2021 and September 2022 were analyzed retrospectively.The univariate and multivariate Cox proportional hazards regression analysis were used to evaluate the prognostic factors for progression-free survival(PFS).The adverse events of treatment were summarized.Results:In the 70 patients,30 patients received Abemaciclib for more than 6 months,with an objective response rate of 44.3%and a disease control rate of 67.1%.The HR for PFS in the Palbociclib to Abemaciclib group versus the Abemaciclib first-line group was 5.4(95%CI was 1.1 to 26.4,P=0.04).The most common adverse events were leucopenia(42.9%)and abdominal pain diarrhea(10.0%).Conclusion:In HR+/HER2-breast cancer patients,the combination of Abemaciclib and endocrine therapy was highly effective controlled side-effect and well tolerated.

关 键 词：乳腺癌 细胞周期蛋白依赖性激酶4/6抑制剂 无进展生存期 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]